Al Hammadi Co. for Development and Investment reported a net profit of SAR 105.6 million for the first nine months of 2015, an 11 percent jump year-on-on-year (YOY) due to higher revenue, expanding its services to patients, as well as the launch of Al-Hammadi Al-Suweidi Hospital in August.
Item | 9m 2014 | 9m 2015 | Change |
---|---|---|---|
Revenues | 352.53 | 403.64 | 14.5 % |
Gross Income | 153.13 | 172.17 | 12.4 % |
Operating Income | 96.43 | 103.17 | 7.0 % |
Net Income | 95.24 | 105.58 | 10.9 % |
Average Shares | 160.00 | 160.00 | - |
EPS (Riyals) | 0.60 | 0.66 | 10.9 % |
The Saudi-listed company, which invests in hospitals, reported a net profit of SAR 27.7 million during Q3-2015, marking a nine percent increase compared to the same quarter of the previous year. However, net profit dropped 25 percent compared to the previous quarter on seasonal impact and higher operating costs.
Item | Q3 2014 | Q3 2015 | Change |
---|---|---|---|
Revenues | 108.83 | 136.80 | 25.7 % |
Gross Income | 44.74 | 57.97 | 29.6 % |
Operating Income | 24.77 | 31.92 | 28.8 % |
Net Income | 25.42 | 27.69 | 8.9 % |
Average Shares | 160.00 | 160.00 | - |
EPS (Riyals) | 0.16 | 0.17 | 8.9 % |
Period | Revenues | Change | Gross Income | Change | Operating Income | Change |
---|---|---|---|---|---|---|
Q1 2015 | 129.48 | 6.1 % | 50.64 | (7.4 %) | 33.35 | (7.3 %) |
Q2 2015 | 137.36 | 12.9 % | 63.56 | 18.4 % | 37.91 | 6.0 % |
Q3 2015 | 136.80 | 25.7 % | 57.97 | 29.6 % | 31.92 | 28.8 % |
Period | Net Income | Change | EPS(Riyal) | Extraordinary Income/Expense | Net Profit Before Unusual Items | EPS Before XO Items |
---|---|---|---|---|---|---|
Q1 2015 | 41.01 | 19.8 % | 0.26 | 9.80 | 31.21 | 0.20 |
Q2 2015 | 36.89 | 3.6 % | 0.23 | - | 36.89 | 0.23 |
Q3 2015 | 27.69 | 8.9 % | 0.17 | - | 27.69 | 0.17 |
Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
---|---|---|---|
Q1 2015 | 41.90 % | 29.13 % | 25.73 % |
Q2 2015 | 42.55 % | 28.68 % | 25.19 % |
Q3 2015 | 42.80 % | 29.71 % | 24.29 % |
Period | Shares Outstanding (M) | EPS (Riyal) | Adjusted EPS (Riyal) | Book Value (BV) |
---|---|---|---|---|
Q1 2015 | 160.00 | 0.85 | 0.79 | 8.51 |
Q2 2015 | 160.00 | 0.86 | 0.80 | 8.27 |
Q3 2015 | 160.00 | 0.87 | 0.81 | 8.44 |
Period | P/E | Adjusted P/E | Price/book |
---|---|---|---|
Q1 2015 | 51.53 | 55.54 | 5.14 |
Q2 2015 | 54.13 | 58.30 | 5.61 |
Q3 2015 | 44.33 | 47.69 | 4.57 |
2015
Period | healthy services and other | Pharmaceutical sales revenue - Pharmacies |
---|
Item | Q3 2015 (e) | Q3 2015 (a) | Change |
---|---|---|---|
Average | 31.17 | 27.69 | (11.2 %) |
Item | Q3 2015 (e) | Q3 2015 (a) | Change |
---|---|---|---|
OSOOL AND BAKHEET | 25.10 | 27.69 | 10.3 % |
AlJazira Capital | 31.40 | 27.69 | (11.8) % |
99Hlala Capital | 37.00 | 27.69 | (25.2) % |
Current | |
Market Cap (M Riyal) | 6,416.00 |
Enterprise Value (EV) (M) | 6,356.52 |
Shares Outstanding ((M)) | 160.00 |
EPS ( Riyal) (TTM) | 2.04 |
Book Value (BV) ( Riyal) | 12.11 |
Par Value ( Riyal) | 10.00 |
Adjusted P/E (Last12) | 24.26 |
P/E (TTM) | 19.67 |
Price/book | 3.31 |
Return on Average Assets (%) (TTM) | 12.6 |
Return on Average Equity (%) (TTM) | 17.3 |
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}